Enlil Achieves Record-Setting Q2 2026 Amid Strong Customer Growth and Expansions

Enlil, Inc., a company that offers an AI-driven development traceability platform catering to the needs of medical device and life sciences organizations, has achieved a remarkable milestone by posting its strongest revenue quarter to date. The second quarter of 2026 witnessed the addition of five new customers while existing clients renewed their subscriptions and expanded their use of Enlil's functionalities.

Momentum in Customer Growth

The growth trajectory demonstrated by Enlil is not purely based on securing new clients; it significantly stems from the deeper integration and increased usage of the platform by current customers. For instance,
Swan EndoSurgical Robotics, which initially licensed Enlil last year for implementing document control solutions, has renewed its agreement for an extended multi-year term and has also broadened its user base. Moreover, Swan has opted to enhance its utilization of Enlil by integrating additional features, such as the SolidWorks API, Milestone View, and Ask Lily, the AI capability offered by Enlil.

Enlil's successes are indicative of a broader trend, showing existing customers not only increasing the number of users on the platform but also expanding their adoption of various modules, integrations, and AI capabilities. As these organizations advance, they are utilizing Enlil to include more participants in their engineering, product development, and manufacturing processes. This gradual yet steady adoption highlights the value customers place on the flexibility and interconnected nature of Enlil's technology.

A Competitive Platform for MedTech Innovation

In an exciting development, Advanced NanoTherapies (ANT) selected Enlil as their development traceability platform, further solidifying Enlil's reputation as a go-to solution for MedTech incubators and innovation hubs. ANT, which is backed by T45 Labs in Silicon Valley, joins a roster of other T45 portfolio companies that have leveraged Enlil to facilitate their operational processes. The advantage of using a shared platform enables varying organizations at different developmental stages to maintain consistency while adapting to their unique operational frameworks, making it an essential tool for innovation.

Marwan Berrada-Sounni, Founder and Managing Partner of T45 Labs, commented, "At T45 Labs, we strive to provide our teams with the infrastructure needed for rapid advancement in technology, ensuring compliance with the highest standards. The flexibility and connectivity offered by Enlil lays a solid foundation for quality and traceability. With ANT joining the ranks of companies using Enlil, our portfolio will benefit from a cohesive platform that supports growth while speeding up development cycles."

Emphasizing the Need for Adaptable Solutions

Enlil’s recent achievements also underline a crucial shift among growing MedTech enterprises. Los Angeles Biosciences (LABS), a startup focused on surgical solutions and in a phase of expansion following a successful seed funding round, is making a strategic choice to partner with Enlil after finding limitations with a competing quality management system. LABS’s decision highlights the demand for flexible solutions that can evolve with an organization’s development needs, in contrast to traditional systems that may not accommodate dynamic operational realities.

Derya Kelter, Co-Founder and CEO of LABS, shared, "Our team was looking beyond just a software solution; we needed a platform that aligns with our developmental processes and a trusted partner to support our growth trajectory. Enlil stands out by unifying quality management, product lifecycle insights, and development traceability in a cohesive manner, which was instrumental for our commitment to them."

A Platform Tailored for the Future

The evolution of Enlil reflects a shift from conventional quality management applications to a comprehensive development traceability platform. Customers are increasingly moving away from basic document control towards far-reaching integrations across engineering functionalities, milestone management, and product lifecycle processes, powered by AI. By merging various product-related elements, Enlil provides continuous visibility, ensuring informed decision-making throughout product development.

Cutting-edge features like Ask Lily provide valuable insights throughout the product lifecycle while Milestone View consolidates progress tracking with evidence-based recordkeeping. This system's integration capabilities, such as with SolidWorks, enhance its usefulness by solidifying design and documentation connections, ultimately supporting compliance during various stages of product development.

Looking Ahead

As Enlil closes the first half of 2026, the company showcases a rapidly expanding customer base, a growing adoption rate among existing users, and significant developments across the medical device development lifecycle. This trajectory signifies a robust growth model for Enlil as it moves forward into the upcoming months, reinforcing its position in the MedTech landscape.

Enlil's mission remains clear: to empower innovators in the MedTech sector by managing complexities, mitigating risks, and scaling compliance as they journey from concept to market.

For more information on Enlil and its innovative solutions, visit enlil.com.